Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
05 November 2024 | Story Jacky Tshokwe | Photo Supplied
BUAN Delegates
Botswana University of Agriculture and Natural Resources (BUAN) delegates that recently visited the University of the Free State to solidify a collaboration.

During an inspiring journey, a delegation from the University of the Free State (UFS) recently visited the Botswana University of Agriculture and Natural Resources (BUAN) with an ambitious goal: to solidify a collaboration that was sparked during the visit of BUAN’s Vice-Chancellor to the UFS and subsequent discussions in Namibia. The atmosphere was one of shared purpose and excitement as the UFS representatives, led by the Dean of the Faculty of Natural and Agricultural Sciences, the Vice-Dean: Agriculture, and the Vice-Dean: Postgraduate and Research, embarked on this significant academic endeavour.

This visit was not just a formal gesture, it was a step towards tangible, mutual benefits for students and staff of both institutions. The discussions between the UFS and the BUAN leadership, which centred around possibilities for student and staff exchanges and shared access to specialised equipment, pointed to the potential of creating a dynamic bridge between South African and Botswana academia. This partnership envisions collaborative supervision of postgraduate students, creating opportunities for intellectual growth that transcends borders. The two universities also explored joint funding applications and research avenues, with particular interest in BUAN’s innovative Meat Institute and AgroVolts solar panel project. Seeing the BUAN’s progress in renewable energy left the UFS team particularly impressed, reflecting the possibilities for sustainable development and resource-sharing that a partnership could yield.

During the discussions, the UFS delegation had a pivotal meeting with the BUAN’s Acting Deputy Vice-Chancellor: Academic and Research, Prof Samodimo Ngwako, who had previously visited the UFS. His familiarity with the UFS’ resources and vision made him an invaluable advocate for bridging the two institutions, highlighting how their strengths could complement each other. Prof Ngwako’s insights helped BUAN staff visualise the meaningful exchange of expertise and resources that could benefit both student bodies and contribute to third-stream income generation.

With the way forward clear, both the UFS and BUAN teams agreed on ‘quick steps’ to launch the collaboration – the swift signing of a Memorandum of Understanding (MoU), followed by the first exchange of students and staff, and the launch of co-supervised research projects. While specific timelines and milestones are to be confirmed post-MoU, both teams are keen on joint funding applications, especially in areas relevant to agricultural and natural resources both within Africa and beyond. This partnership, once formalised, is expected to solidify both universities as leading research hubs in agriculture and natural resources, advancing each institution’s standing on the continent.

Reflecting on the visit, the UFS delegation felt a deep sense of optimism. The collaboration between the UFS and the BUAN aligns seamlessly with the UFS’ broader vision for strengthening ties with African universities, showcasing a forward-thinking approach to partnerships. As the journey towards meaningful collaboration progresses, the shared enthusiasm witnessed at the BUAN serves as a hopeful reminder that academia – when united by common goals – can drive impactful change for students, faculty, and communities on both sides of the border.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept